Mesoblast Ltd., of Melbourne, Australia, said the FDA granted regenerative medicine advanced therapy designation to its mesenchymal precursor cell (MPC) therapy for the treatment of heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices (LVADs).